An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Binimetinib (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Therapeutic Use
- Sponsors Novartis
- 28 Dec 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 20 Oct 2014 Planned End Date changed from 1 Mar 2017 to 1 May 2017 according to ClinicalTrials.gov rcord.
- 20 Oct 2014 Planned primary completion date changed from 1 Mar 2017 to 1 May 2017 according to ClinicalTrials.gov record.